

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-46 (Cancelled)

47 (Currently amended). A method to treat a living body suffering from a disease selected from the group consisting of asthma, rejection reactions relating to grafting organs or tissues, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory ~~disease~~ diseases, comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises constant regions, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said constant regions being not equal to ~~and does not completely contain~~ the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

48 (Currently amended). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment, comprising administering an effective amount of a composition to

the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises constant regions, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said constant regions being not equal to ~~and does not completely contain~~ the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

49(Currently amended). A method to treat a living body suffering from a disease selected from the group consisting of asthma, rejection reactions relating to grafting organs or tissues, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory disease diseases, comprising administering an effective amount of a composition to the living body, ~~wherein~~ said composition ~~comprises~~ comprising (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises constant regions, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said constant regions being not equal to ~~and does not completely contain~~ the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, ~~and~~ wherein the

interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

50 (Currently amended). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment, comprising administering an effective amount of a composition to the living body, ~~wherein~~ said composition ~~comprises~~ comprising (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises constant regions, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said constant regions being not equal to ~~and does not completely contain~~ the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, and wherein the interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

Appln. No. 09/924,099

Amd. dated February 18, 2004

Reply to Office Action of August 27, 2003

51(New). The method of claim 47, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.

52(New). The method of claim 48, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.

53(New). The method of claim 49, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.

54(New). The method of claim 50, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.